How to Value an ABA Therapy Business in 2026

Applied Behavior Analysis therapy for autism spectrum disorder has become one of the most actively consolidated healthcare verticals in the country. PE firms have deployed billions into ABA platforms, and the fundamentals justify the enthusiasm: growing prevalence, expanding insurance mandates, chronic provider shortages, and a fragmented market of small operators ripe for consolidation.

But ABA valuations are tricky. The multiples look attractive on paper — 6-12x EBITDAdepending on scale — but the underlying economics are uniquely constrained by workforce availability. I've worked on ABA transactions where the deal thesis was compelling and the financials were strong, yet the valuation hinged almost entirely on one question: can you keep your BCBAs?

Why ABA Is a PE Magnet

The PE thesis for ABA is built on several converging tailwinds that have sustained a decade-long consolidation wave.

Autism prevalence keeps rising. The CDC now estimates 1 in 36 children is diagnosed with ASD, up from 1 in 44 just a few years ago. Whether this reflects true prevalence increases or improved diagnostic awareness, the practical effect is the same: surging demand for ABA services with no sign of deceleration.

Insurance mandates have expanded dramatically. All 50 states now have some form of autism insurance mandate requiring commercial payers to cover ABA therapy. This regulatory tailwind converted ABA from a primarily self-pay or Medicaid-funded service into a commercially insured service with better reimbursement rates and more predictable collections.

The market is massively fragmented. There are thousands of small ABA providers, most operating in a single metro with 5-20 BCBAs. The top 10 providers still control less than 15% of the market. For PE firms, that fragmentation means years of acquisition runway.

The Valuation Framework

ABA businesses are valued on EBITDA multiples, with the range driven primarily by scale, growth trajectory, and workforce stability.

• Small single-site operators (under $3M revenue): 4-6x EBITDA. At this size, you're selling a practice, and the buyer pool is mostly other clinicians or small regional operators.
• Mid-size regional providers ($3-15M revenue): 6-9x EBITDA. This is the sweet spot for PE bolt-on acquisitions. You have enough scale to matter but aren't so large that you command platform pricing.
• Large multi-state platforms ($15M+ revenue): 8-12x EBITDA. At this level, you attract platform-level PE interest. Multiple states, strong management infrastructure, and proven ability to recruit and retain BCBAs.

The key nuance in ABA valuation is that EBITDA can be volatile. Revenue is driven by billable hours, which are driven by clinical staff availability and client census. Lose three BCBAs in a quarter, and your revenue can drop 15-20% within months as their caseloads can't be backfilled. Buyers normalize EBITDA for staff turnover events and look at trailing trends carefully.

The BCBA Shortage: The #1 Constraint

Board Certified Behavior Analysts are the licensed clinicians who supervise ABA therapy programs, develop treatment plans, and oversee Registered Behavior Technicians (RBTs) who deliver direct therapy. There are roughly 60,000 BCBAs in the US, and demand far outstrips supply.

This shortage is the defining constraint in ABA valuation. Every other metric — client census, billable hours, revenue growth — is downstream of your ability to recruit and retain BCBAs. A company with 20 BCBAs and 15% annual turnover is fundamentally more valuable than one with 20 BCBAs and 35% turnover, even if their current-year financials are identical.

BCBA turnover above 30% is a red flag that will compress your multiple by 1-2x EBITDA or more. Buyers know that replacing a BCBA takes 3-6 months, during which their caseload either sits vacant (lost revenue) or gets distributed to already-stretched supervisors (quality and burnout risk). The cost of BCBA turnover compounds far beyond the recruiting expense.

The companies commanding top multiples have cracked the retention code: competitive base salaries ($85-110K for experienced BCBAs), manageable caseloads (12-15 clients per BCBA), clinical autonomy, professional development budgets, and a culture that treats BCBAs as professionals rather than revenue-generating units. Buyers can feel the difference during diligence, and they pay for it.

Key Operating Metrics Buyers Analyze

Active client census is your top-line capacity indicator. More important than total enrolled clients is the number actively receiving services (billing at least 10 hours/week). A company with 200 enrolled clients but only 120 active is showing a capacity or staffing problem.

Billable hours per BCBA measures clinical efficiency. BCBAs split time between direct therapy, supervision of RBTs, treatment planning, and administrative work. High-performing companies achieve 25-28 billable hours per BCBA per week. Below 20 billable hours signals inefficiency or excessive administrative burden.

RBT-to-BCBA ratio determines leverage. Each BCBA typically supervises 6-10 RBTs. Companies with healthy ratios (8:1 to 10:1) generate more revenue per BCBA because each BCBA oversees more billable RBT hours. Ratios above 12:1 risk compliance issues and quality concerns.

Authorization utilization rate— the percentage of authorized hours actually delivered — is a critical metric many sellers overlook. Insurance companies authorize a specific number of therapy hours per client. If you're only delivering 60% of authorized hours (because you can't staff the cases), buyers see both a current inefficiency and a growth opportunity. Utilization above 80% signals operational excellence.

Payer Mix: Commercial vs. Medicaid

Payer mix is the second most important valuation driver after workforce stability. Commercial insurance (BCBS, UnitedHealthcare, Aetna, Cigna) reimburses ABA at significantly higher rates than Medicaid — often 40-60% higher for the same CPT codes.

Companies with 60%+ commercial payer mix trade at premium multiples. The margins are higher, the collections are faster, and the reimbursement rates are more predictable. Medicaid-heavy practices (50%+ Medicaid) face reimbursement risk from state budget pressures and often have lower margins that compress EBITDA multiples by 1-3x.

That said, Medicaid isn't inherently bad. Some states (Massachusetts, New Jersey, California) have relatively generous Medicaid ABA rates. And Medicaid clients tend to have higher authorized hours and longer treatment durations, providing revenue stability. The key is knowing your state's Medicaid ABA reimbursement landscape and how it compares to commercial rates.

State Licensing and Geographic Expansion

ABA therapy is regulated at the state level, and licensing requirements vary significantly. Some states require facility licensure, others only individual BCBA licensure. Telehealth regulations for ABA supervision differ by state. Medicaid waiver programs have different eligibility criteria and reimbursement structures.

This regulatory complexity is actually a moat for established operators. Entering a new state requires navigating licensing, credentialing with payers (which can take 6-12 months), and recruiting local BCBAs. Companies that have already done the hard work of establishing multi-state operations are more valuable because they've already cleared regulatory hurdles that take competitors a year or more to replicate.

PE buyers evaluate geographic footprint carefully. A company operating in states with strong autism mandates, favorable reimbursement, and growing populations (Texas, Florida, Arizona, North Carolina) is more attractive than one concentrated in states with Medicaid budget pressures or saturated provider markets.

In-Home vs. Center-Based: The Model Matters

ABA therapy is delivered in two primary settings: in-home (therapists travel to the client's residence) and center-based (clients come to a clinic). Each model has different economics and valuation implications.

Center-based programs have higher fixed costs (facility lease, buildout, equipment) but offer better clinical control, staff utilization, and scalability. PE buyers generally prefer center-based models because they're easier to standardize and replicate across geographies.

In-home programs have lower overhead but face travel time inefficiency and higher therapist turnover (driving between homes is a leading cause of RBT burnout). Hybrid models — center-based with some in-home capacity — often command the best valuations because they offer flexibility while maintaining operational efficiency.

The Bottom Line

ABA therapy businesses trade at 6-12x EBITDA, with the range driven primarily by scale, BCBA retention, and payer mix. The sector remains one of the most active PE consolidation verticals in healthcare, supported by growing demand, expanding insurance coverage, and massive market fragmentation. But unlike other healthcare verticals where the asset is patient relationships or facility infrastructure, the asset in ABA is your clinical workforce. Companies that invest in BCBA retention, maintain manageable caseloads, and build a culture that clinicians don't want to leave are the ones that command top-tier multiples. Everything else is downstream of that.